AU2001251613A1 - Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers - Google Patents

Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Info

Publication number
AU2001251613A1
AU2001251613A1 AU2001251613A AU5161301A AU2001251613A1 AU 2001251613 A1 AU2001251613 A1 AU 2001251613A1 AU 2001251613 A AU2001251613 A AU 2001251613A AU 5161301 A AU5161301 A AU 5161301A AU 2001251613 A1 AU2001251613 A1 AU 2001251613A1
Authority
AU
Australia
Prior art keywords
assessment
therapy
prevention
compositions
identification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001251613A
Inventor
Andrew Bolt
Jeffrey L. Brown
James Lillie
Christophe Van Huffel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2001251613A1 publication Critical patent/AU2001251613A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
AU2001251613A 2000-04-14 2001-04-13 Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers Abandoned AU2001251613A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19753800P 2000-04-14 2000-04-14
US60/197,538 2000-04-14
PCT/US2001/012132 WO2001079556A2 (en) 2000-04-14 2001-04-13 Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Publications (1)

Publication Number Publication Date
AU2001251613A1 true AU2001251613A1 (en) 2001-10-30

Family

ID=22729805

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001251613A Abandoned AU2001251613A1 (en) 2000-04-14 2001-04-13 Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Country Status (3)

Country Link
US (1) US20020110815A1 (en)
AU (1) AU2001251613A1 (en)
WO (1) WO2001079556A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1268791A2 (en) * 2000-03-23 2003-01-02 Immusol Incorporated Brca-1 regulators and methods of use
US20030050441A1 (en) * 2000-09-25 2003-03-13 Millennium Pharmaceuticals, Inc. 49938, a novel human phospholipid transporter and uses therefor
AU2001271621A1 (en) 2000-06-28 2002-01-08 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
JP2005505258A (en) 2001-06-21 2005-02-24 イシス・イノベイション・リミテッド ANGE gene in atopy
US20030068691A1 (en) * 2001-07-16 2003-04-10 Applera Corporation Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
JPWO2003044196A1 (en) * 2001-11-20 2005-03-24 第一製薬株式会社 Post-synaptic protein
GB0129846D0 (en) * 2001-12-13 2002-01-30 Eirx Therapeutics Ltd Tgnp
FR2836687A1 (en) 2002-03-04 2003-09-05 Gene Signal GENES INVOLVED IN THE REGULATION OF ANGIOGENESIS, PHARMACEUTICAL PREPARATIONS CONTAINING SAME AND THEIR APPLICATIONS
AU2003211696A1 (en) * 2002-03-07 2003-09-16 Bf Research Institute, Inc. p18ABetarP GENE AND p18ABetarP PROTEIN, NOVEL GENE/PROTEIN (p60TRP) INTERACTING THEREWITH TO INHIBIT CELL DEATH AND CELL DEATH PROMOTER
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
EP1588140A4 (en) * 2002-04-26 2007-06-27 Ludwig Inst Cancer Res Cancer-associated nucleic acids and polypeptides
EP1576177A4 (en) * 2002-05-17 2007-12-26 Baylor College Medicine Differential patterns of gene expression that predict for docetaxel chemosensitivity and chemoresistance
WO2004020620A1 (en) * 2002-08-13 2004-03-11 Bayer Healthcare Ag Regulation of human esterase
JP2005065687A (en) 2003-01-23 2005-03-17 National Institute Of Advanced Industrial & Technology beta1,3-N-ACETYL-D-GALACTOSAMINE TRANSFERASE PROTEIN, NUCLEIC ACID ENCODING THE SAME, AND METHOD FOR TESTING CANCERATION USING THE SAME
EP1689888A2 (en) * 2003-10-23 2006-08-16 Illumigen Biosciences Inc. Detection of mutations in a gene associated with resistance to viral infection, oas1
US7566546B2 (en) * 2004-02-17 2009-07-28 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
US20050255481A1 (en) * 2004-05-11 2005-11-17 Xiao-Jun Ma Progesterone receptor transcript sequences
UA95446C2 (en) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Mutations in oas1 genes
EP2188391A1 (en) * 2007-08-14 2010-05-26 F. Hoffmann-Roche AG Predictive markers for egfr inhibitor treatment
WO2009028968A1 (en) * 2007-08-28 2009-03-05 Auckland Uniservices Limited Cell marker of melanocyte cell lineage and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736326A (en) * 1987-05-05 1998-04-07 City Of Hope Method of detecting resistance to chemo therapeutic agents in cancer patients
CA2132500A1 (en) * 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours
AU2001245939A1 (en) * 2000-03-24 2001-10-08 Millennum Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Also Published As

Publication number Publication date
US20020110815A1 (en) 2002-08-15
WO2001079556A3 (en) 2003-07-10
WO2001079556A2 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
AU2001229340A1 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001241541A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2074201A (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002337657A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2002219782A1 (en) Diindolylmethane and c-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU7701100A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2074101A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers